Additional file 5 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
2021 · doi:10.6084/m9.figshare.14821141.v1 · W6939610177
article OA: green CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper presents a summary of pharmacodynamic parameters measured at various assessment points during a 24-week phase 2 study of relugolix in women with endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 5. Summary of pharmacodynamic parameters at each assessment point.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-13T18:33:16.088889+00:00
License: CC0 · commercial use OK